OncoCyte SG&A Expenses 2014-2025 | OCX
OncoCyte sg&a expenses from 2014 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
| OncoCyte Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $14 |
| 2023 | $14 |
| 2022 | $23 |
| 2021 | $23 |
| 2020 | $23 |
| 2019 | $15 |
| 2018 | $9 |
| 2017 | $12 |
| 2016 | $5 |
| 2015 | $4 |
| 2014 | $1 |
| 2013 | $1 |
| OncoCyte Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $4 |
| 2024-12-31 | $4 |
| 2024-09-30 | $4 |
| 2024-06-30 | $3 |
| 2024-03-31 | $4 |
| 2023-12-31 | $2 |
| 2023-09-30 | $3 |
| 2023-06-30 | $4 |
| 2023-03-31 | $4 |
| 2022-12-31 | $5 |
| 2022-09-30 | $6 |
| 2022-06-30 | $6 |
| 2022-03-31 | $6 |
| 2021-12-31 | $-3 |
| 2021-09-30 | $8 |
| 2021-06-30 | $11 |
| 2021-03-31 | $7 |
| 2020-12-31 | $5 |
| 2020-09-30 | $7 |
| 2020-06-30 | $5 |
| 2020-03-31 | $6 |
| 2019-12-31 | $5 |
| 2019-09-30 | $4 |
| 2019-06-30 | $4 |
| 2019-03-31 | $3 |
| 2018-12-31 | $3 |
| 2018-09-30 | $1 |
| 2018-06-30 | $2 |
| 2018-03-31 | $2 |
| 2017-12-31 | $2 |
| 2017-09-30 | $5 |
| 2017-06-30 | $2 |
| 2017-03-31 | $3 |
| 2016-12-31 | $2 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $2 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $0 |
| 2014-12-31 | |
| 2013-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.095B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $135.906B | 25.49 |
| Elevance Health (ELV) | United States | $86.723B | 11.19 |
| CVS Health (CVS) | United States | $81.012B | 10.07 |
| Cencora (COR) | United States | $56.449B | 19.64 |
| DiDi Global (DIDIY) | China | $21.556B | 32.71 |
| Natera (NTRA) | United States | $21.538B | 0.00 |
| BioMerieux (BMXMF) | France | $15.890B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.928B | 0.00 |
| Solventum (SOLV) | United States | $12.646B | 13.39 |
| CochLear (CHEOY) | Australia | $11.378B | 0.00 |
| Revvity (RVTY) | United States | $10.658B | 18.34 |
| ICON (ICLR) | Ireland | $10.521B | 9.78 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Doximity (DOCS) | United States | $9.725B | 45.30 |
| Avantor (AVTR) | United States | $8.797B | 12.78 |
| HealthEquity (HQY) | United States | $8.702B | 42.81 |
| Medpace Holdings (MEDP) | United States | $8.476B | 22.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.311B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.662B | 13.05 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 27.19 |
| BrightSpring Health Services (BTSG) | United States | $4.149B | 38.40 |
| Bausch + Lomb (BLCO) | Canada | $4.054B | 23.90 |
| Sotera Health (SHC) | United States | $3.474B | 19.74 |
| Alignment Healthcare (ALHC) | United States | $3.041B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.026B | 39.35 |
| Concentras Parent (CON) | United States | $2.772B | 16.02 |
| Organon (OGN) | United States | $2.397B | 2.55 |
| Ardent Health Partners (ARDT) | United States | $2.071B | 8.83 |
| GeneDx Holdings (WGS) | United States | $2.032B | 78.26 |
| Premier (PINC) | United States | $1.892B | 14.36 |
| Progyny (PGNY) | United States | $1.843B | 40.57 |
| PACS (PACS) | United States | $1.512B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.400B | 28.00 |
| Pediatrix Medical (MD) | United States | $1.216B | 9.25 |
| Teladoc Health (TDOC) | United States | $1.214B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.995B | 0.00 | |
| CareDx (CDNA) | United States | $0.946B | 14.77 |
| Nutex Health (NUTX) | United States | $0.934B | 14.11 |
| Agilon Health (AGL) | United States | $0.919B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.808B | 7.57 |
| Embecta (EMBC) | United States | $0.615B | 4.15 |
| LifeMD (LFMD) | United States | $0.555B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.552B | 0.00 |
| Enhabit (EHAB) | United States | $0.532B | 43.75 |
| SBC Medicals (SBC) | United States | $0.532B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.474B | 10.67 |
| Sonida Senior Living (SNDA) | United States | $0.460B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.389B | 0.00 |
| Oncology Institute (TOI) | United States | $0.285B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.240B | 0.00 |
| Beauty Health (SKIN) | United States | $0.205B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| KindlyMD (NAKA) | United States | $0.136B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.112B | 0.00 |
| So-Young (SY) | China | $0.088B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.067B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.058B | 0.00 |
| Biodesix (BDSX) | United States | $0.044B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| ModivCare (MODV) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |